Family History for Public Health and Preventive Medicine: Developing a Research Agenda Paula Yoon, ScD, MPH Office of Genomics & Disease Prevention CDC.

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

April 5 th, 2011 FAMILY HISTORY AND THE PUBLICS HEALTH.
Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
The Human Genome Project
Lecture 3 Validity of screening and diagnostic tests
National Center for Chronic Disease Prevention and Health Promotion Division of Nutrition, Physical Activity, and Obesity Healthy Communities: Healthy.
Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.
ROSALIND CHUANG, M.D. DEPARTMENT OF NEUROLOGY STANFORD UNIVERSITY Informed consent for genetic testing: Genetics 210.
Integrating Genomics into Clinical Practice Jan Dorman, PhD University of Pittsburgh School of Nursing
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
What Happens to the Performance of a Diagnostic Test when the Disease Prevalence and the Cut-Point Change? Pathological scores Healthy scores Healthy population.
TUTORIAL SCREENING Dr. Salwa Tayel, Dr. A. Almazam, Dr Afzal Mahmood
Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!
Healthy Child Development Suggestions for Submitting a Strong Proposal.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Accomplishments & Outcomes: Genomics Successes in Oregon Amy Zlot Oregon Genetics Program.
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
Environmental Health III. Epidemiology Shu-Chi Chang, Ph.D., P.E., P.A. Assistant Professor 1 and Division Chief 2 1 Department of Environmental Engineering.
Statistics for Health Care
Surveillance. Definition Continuous and systematic process of collection, analysis, interpretation, and dissemination of descriptive information for monitoring.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Family History as a Screening Tool for Public Health and Preventive Medicine Paula W. Yoon, ScD, MPH Office of Genomics & Disease Prevention, CDC ACCE.
What is personal genetics? What might it mean for me, my family and society? Personal Genetics Education Project (pgEd) Harvard Medical School
Documenting the Family History: An Overview of Available Tools Kristin Peterson, MS, CGC Office of Genomics and Disease Prevention Centers for Disease.
Screening and Early Detection Epidemiological Basis for Disease Control – Fall 2001 Joel L. Weissfeld, M.D. M.P.H.
Integrating Genomics into Clinical Practice Janice S. Dorman, PhD University of Pittsburgh School of Nursing.
Ethical, Legal, and Social Implications of the Critical Congenital Heart Defect Screening Program Emily Reddy, OTR New England Genetics Collaborative (NEGC)
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Family History for Public Health and Preventive Medicine Paula W. Yoon, ScD, MPH Office of Genomics & Disease Prevention, CDC.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
Adult-Onset Disease The Example of Colon Cancer Summer, 2012.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
Genetic-Environmental Interaction: Implications for Osteoporosis Prevention Strategies.
Framework for Measurement of Universal Health Coverage Ties Boerma, WHO Beijing, 3 November 2012 Based on meeting at Rockefeller Center, Bellagio,
Human Genome Project Daniel Ospina Joaquín Llano.
Nies and Nies and McEwen: Chapter 4: ATI: Chapter 3 Epidemiology.
The Problem with Individual Risk Beverly Rockhill, Ph.D. Department of Epidemiology University of North Carolina, Chapel Hill.
Risk Prediction of Complex Disease David Evans. Genetic Testing and Personalized Medicine Is this possible also in complex diseases? Predictive testing.
Shaping a Health Statistics Vision for the 21 st Century 2002 NCHS Data Users Conference 16 July 2002 Daniel J. Friedman, PhD Massachusetts Department.
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Recommendation Methods Advisory Committee on Heritable Disorders and Genetic Diseases of Newborns and Children Ned Calonge, M.D., M.P.H.
Cancer 101: A Cancer Education and Training Program for American Indians & Alaska Natives Cancer 101: A Cancer Education and Training Program for American.
Child Health and School Readiness: The Significance of Health Literacy Laurie Martin, ScD, MPH Human Capital Research Collaborative Conference October.
Screening.  “...the identification of unrecognized disease or defect by the application of tests, examinations or other procedures...”  “...sort out.
Estie Vermeulen Screening. Definition Screening is the organized attempt to detect, among apparently healthy people in the community, disorders or risk.
Surveillance Key Points Dr. Oswaldo S. Medina Gómez.
5-6-1 Unit 6: Ethical considerations After completing this unit, you should be able to: Understand the basic ethical principles of working with.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
The Human Genome Project
SCREENING FOR DISEASE. Learning Objectives Definition of screening; Principles of Screening.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
WHAT IS THE IMPACT OF THE HUMAN GENOME PROJECT FOR DRUG DEVELOPMENT? Arman & Fin.
Rene Descartes: “I think; therefore I am.”. 3.3: Data Ethics Statistics Chap 3: Designing Experiments.
James E. Haddow, M.D. Women & Infants Hospital Alpert Medical School of Brown University BROWN Women & Infants’ EDUCATIONAL CHALLENGES PRESENTED BY NEW.
1 Copyright © 2012 by Mosby, an imprint of Elsevier Inc. Copyright © 2008 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 11 Genomics in Public Health.
Lesson 3 Page 1 of 24 Lesson 3 Considerations in Planning Public Health Surveillance.
Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.
DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M
Central American Certificate Course: HIV Monitoring and Evaluation for HIV/AIDS Policy and Program Management BZ Unit 2 – Post test CR ES GT NI PA January.
Epidemiology Section APHA Tuesday, Nov. 6, 2007
Ethical Principles of Research
Figure 2 The US Centers for Disease Control and
Chapter 12 Health Risk Appraisal.
11/20/2018 Study Types.
Applicants’ Orientation Meeting
Family History to Promote Individual Health
Genomic Medicine in Community Health: Protecting Human Rights
Presentation transcript:

Family History for Public Health and Preventive Medicine: Developing a Research Agenda Paula Yoon, ScD, MPH Office of Genomics & Disease Prevention CDC

Could disease information about a person’s close relatives be used to predict their own risk for specific diseases? Why this workshop -- Would individuals who may be at above average risk benefit from targeted interventions beyond what is recommended for the population at large ?

Purpose of the workshop -- Discuss the potential of family history for disease prevention and determine what information is needed in order to assess the validity and utility of this approach.

Workshop goals --  Identify diseases and selection criteria  Describe specifications for a FH tool  Identify knowledge gaps in AV, CV, CU  Describe ethical, legal and social implications  Describe studies needed to fill knowledge gap  Identify potential sources of existing data  Describe new studies that may be needed

What is family history?  reflects the consequences of genetic susceptibilities, shared environment, and common behaviors  ranges from knowing whether a parent or sibling had a specific disease to a very detailed pedigree analysis

Family history for public health and preventive medicine  simple, easily applied, inexpensive  can identify people at high and moderate risk  can be used in combination with other risk factors  useful for targeting interventions  positively influences healthy behaviors

Family history for public health and preventive medicine  population-based uses of FH  e.g., Behavioral Risk Factor Surveillance System  stratify risk factors by FH  target interventions  evaluate trends over time

Prevalence and relative risk estimates due to family history for chronic diseases CVD58 mill2.0 – 5.4 Breast cancer3 mill wom2.1 – 3.9 Colorectalincid = 130, – 4.9 Prostateincid = 200, – 11.0 Melanoma200, – 4.3 Type II diabetes13 mill2.4 – 4.0 Osteoporosis8 mill wom2.0 – mill men Asthma17 mill3.0 – 7.0

Risk estimates for colorectal cancer for 3 family history risk groups Average Moderate High (no FH) (one 1° relat) (>one 1° relat) FH preval9/101/101/ /8,000 Absolute ~1 Relativeref ~30 Attributable

Evaluation framework

Analytic validity -- How accurately and reliably does the FH tool identify disease among a person’s relatives? FH tool “gold standard” A B - C D analytic sensitivity = A / (A+C) analytic specificity = D / (B+D)

Clinical validity -- How accurate and reliable is FH for stratifying disease risk and predicting future disease? FH Future disease A B - C D clin sensitivity = A / (A+C) clin specificity = D / (B+D) PPV = A / (A+B) NPV = D / (C+D)

Clinical utility -- What are the benefits and risks accruing from both negative and positive family history?  will targeted interventions based on FH prevent disease?  is FH useful for changing behavior?  is the approach cost-effective?  are there risks associated with collecting and using FH?

Ethical, legal and social implications --  stigma associated with above average risk  psychological impact of risk label  discrimination or adverse effects on personal and family life  informed consent requirements  safeguards to protect privacy and confidentiality

Evaluation framework

Potential of family history Jim Fixx